Clinical Trial Finder

Inclusion Criteria:

• - Signed informed consent obtained.

• - Age ≥ 18 years, any gender.

• - Pathologically confirmed malignant tumors, including: - Glioblastoma.

• - Head and neck squamous cell carcinoma.

• - Non-small cell lung cancer.

• - Esophageal cancer.

• - Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy).

• - Measurable disease with at least one residual tumor lesion.

• - ECOG performance status of 0-1.

• - No contraindications to [18F]AlF-NOTA-PCP2 PET/CT imaging.

• - Willing and able to comply with study procedures and follow-up visits.

Exclusion Criteria:

• - Participation in another interventional clinical trial.

• - Failure to recover from toxic effects or complications of prior interventions (≤ grade 1 or baseline levels, excluding fatigue or hair loss).

• - Pregnant or breastfeeding women.

• - Severe or uncontrolled systemic diseases, including: - Major, symptomatic arrhythmias or significant ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, or ventricular arrhythmias).

• - Unstable angina or congestive heart failure (NYHA class ≥ 2).

• - Any arterial thrombotic or embolic events within 6 months before enrollment (e.g., myocardial infarction, cerebrovascular accident, transient ischemic attack).

• - Active or uncontrolled infections requiring systemic treatment.

• - Severe psychiatric disorders affecting study participation.

• - Any medical history, laboratory abnormality, or condition that may: - Interfere with study results.

• - Affect patient participation.

• - Pose an unacceptable risk as determined by the investigator.

• - Women of childbearing potential without a negative pregnancy test prior to study entry.

• - Known allergy or hypersensitivity to [18F]AlF-NOTA-PCP2 or any component of the radiopharmaceutical.

This phase I/II clinical trial is designed to explore the utility of [18F]AlF-NOTA-PCP2 PET/CT in evaluating PD-L1 expression and its prognostic implications in patients with malignant tumors (glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer). The study involves at least 20 patients (5 per tumor type) who will undergo a pre-treatment PET/CT scan following an intravenous injection of [18F]AlF-NOTA-PCP2. The primary endpoints include the safety of the imaging protocol and the correlation between [18F]AlF-NOTA-PCP2 uptake (SUV values) and PD-L1 expression determined through immunohistochemistry (IHC). Secondary endpoints explore the dynamic changes in SUV values in patients undergoing multiple scans and their relationship with clinical outcomes. Scientific and Technical Rationale: [18F]AlF-NOTA-PCP2 is a novel radiotracer with high specificity for PD-L1, enabling non-invasive imaging of its expression in vivo. This imaging approach complements traditional immunohistochemical methods by offering whole-body assessment, eliminating the need for repeated biopsies, and providing insights into the tumor microenvironment. This study seeks to validate its application in clinical oncology, bridging molecular imaging with biomarker-guided therapeutic strategies. Study Methods: Patients will receive a single intravenous dose of [18F]AlF-NOTA-PCP2 (adjusted for body weight), followed by a whole-body PET/CT scan after one hour. Images will be analyzed independently by two experienced nuclear medicine specialists. Tumor biopsies will be collected to measure PD-L1 expression via IHC, and blood samples will be assessed for circulating and exosomal PD-L1 biomarkers. For patients undergoing multiple scans, changes in radiotracer uptake will be tracked to monitor treatment response. Data Analysis: SUV values will be correlated with PD-L1 expression levels, clinical factors (e.g., tumor stage, histology), and patient outcomes (PFS, OS). Statistical analyses, performed using SPSS 29.0, will include primary correlations and secondary evaluations of imaging-based dynamic changes and their relationship with therapeutic efficacy. Significance: This trial will provide critical data on the feasibility of [18F]AlF-NOTA-PCP2 PET/CT imaging in clinical oncology. Its potential to stratify patients based on PD-L1 expression and predict therapy response could transform personalized cancer care, optimizing immunotherapy outcomes and minimizing unnecessary treatments. Timeline: Patient enrollment is expected to last 12 months, with an additional 3 months of follow-up for data collection and analysis.

Arms

Interventions